TD Cowen maintains Boston Scientific buy rating, $110 target
TD Cowen reiterated a Buy rating for Boston Scientific (NYSE:BSX) stock, maintaining a price target of $110.00. The stock, currently trading at $98.78, has shown remarkable momentum, reaching new ...
StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)
Research analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a report released on Thursday. The brokerage set a “sell” rating on the biotechnology ...
FY2024 EPS Estimates for RIGL Lifted by Cantor Fitzgerald
Analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a ...
EuropaWire5h
AstraZeneca’s Calquence Gains U.S. Approval for First-Line Treatment of Mantle Cell Lymphoma, Following Positive Phase III Results
AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...